Related Experiment Video
Updated: Jan 14, 2026
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
Pediatric Sarcopenia: What do We Know?
Marília Marques1, Fátima Baptista2
1Hospital Lusíadas Lisboa. Lisboa. & Departamento de Desporto e Saúde. Centro Interdisciplinar de Performance Humana (CIPER). Faculdade de Motricidade Humana. Universidade de Lisboa. Lisboa. Portugal.
Insights
Pediatric sarcopenia, a loss of muscle in children, impacts growth and raises risks for metabolic and cardiovascular diseases. Early detection and intervention through lifestyle changes and new therapies are vital for better child health outcomes.
Area of Science:
- Pediatric Health
- Muscle Physiology
- Developmental Pediatrics
Background:
- Pediatric sarcopenia, initially associated with aging, is increasingly recognized in children and adolescents, especially those with chronic conditions.
- This condition negatively impacts growth, neurodevelopment, and increases the risk of long-term metabolic and cardiovascular diseases.
- Contributing factors include poor prenatal nutrition, low birth weight, genetics, inadequate protein intake, sedentary lifestyles, obesity, and chronic illnesses.
Purpose of the Study:
- To review the current understanding of pediatric sarcopenia, including its causes, consequences, diagnostic challenges, and emerging therapeutic strategies.
- To highlight the importance of early detection and intervention for improving pediatric health outcomes.
Main Methods:
- Review of existing literature on pediatric sarcopenia, encompassing etiological factors, clinical manifestations, diagnostic limitations, and treatment advancements.
- Analysis of current assessment tools and their shortcomings in pediatric populations.
- Exploration of novel therapeutic avenues, including targeted drug delivery, regenerative medicine, and pharmacological interventions.
Main Results:
- Reduced muscle mass in children leads to impaired bone health, delayed growth, and diminished physical performance, affecting quality of life.
- Sarcopenia complicates clinical outcomes in chronically ill children, prolonging hospital stays and increasing complication rates.
- Current diagnostic methods lack standardized pediatric reference values, hindering early detection.
Conclusions:
- Pediatric sarcopenia presents significant short- and long-term health risks, necessitating focused attention.
- Preventive measures include promoting physical activity, balanced nutrition, and healthy lifestyle habits.
- While innovative treatments are emerging, pediatric-specific therapeutic guidelines are still undefined, emphasizing the need for further research and early intervention.
Abstract:
Pediatric sarcopenia is an emerging health issue that affects muscle development, strength, and overall well-being in children and adolescents. While it was initially linked to aging, recent studies highlight its presence in younger populations, particularly among those with chronic conditions. This condition affects growth and neurodevelopment in the short term and is associated with an increased risk of long-term complications, namely metabolic and cardiovascular diseases. Several factors contribute to pediatric sarcopenia, including inadequate prenatal nutrition, low birth weight, genetic susceptibility, insufficient dietary protein intake, sedentary behaviors, obesity, metabolic imbalances, and chronic illnesses. Reduced muscle mass impairs bone health, delays growth spurts, and affects physical performance, which may result in a lower quality of life. In children with chronic diseases, sarcopenia exacerbates clinical outcomes, prolongs hospital stays, and increases the likelihood of complications. Diagnosing sarcopenia in children is complex due to differing growth patterns. Existing assessment methods, such as imaging techniques and body composition analysis, lack standardized reference values tailored to pediatric populations, which makes early detection challenging. Preventive strategies emphasize physical activity, especially resistance exercises (muscle strengthening), reduced screen time, improved dietary habits, and sleep hygiene. Innovative treatments are being explored, including targeted drug delivery to the muscle to minimize side effects, regenerative approaches utilizing nanoparticles, and myostatin inhibitors for stimulating muscle growth. Stem cell therapy and biomaterial-based muscle reconstruction are also under investigation; however, pediatric-specific therapeutic guidelines remain undefined. Early intervention is crucial for reducing its negative effects and fostering healthier developmental paths.
Related Concept Videos
01:09Changes in the Appendicular Skeleton with Age
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:21Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...